MwanzoBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Bei iliyotangulia
CHF 41.15
Bei za siku
CHF 40.60 - CHF 41.45
Bei za mwaka
CHF 32.00 - CHF 49.00
Thamani ya kampuni katika soko
540.62M CHF
Wastani wa hisa zilizouzwa
elfu 17.18
Uwiano wa bei na mapato
47.10
Mgao wa faida
-
Ubadilishanaji wa msingi
SWX
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 36.36M | -19.30% |
Matumizi ya uendeshaji wa biashara | 7.96M | 12.34% |
Mapato halisi | -10.69M | -187.82% |
Kiwango cha faida halisi | -29.41 | -208.81% |
Mapato kwa kila hisa | — | — |
EBITDA | -7.88M | -152.08% |
Asilimia ya kodi ya mapato | 0.08% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 59.93M | -29.21% |
Jumla ya mali | 173.29M | -21.53% |
Jumla ya dhima | 183.29M | -24.12% |
Jumla ya hisa | -10.00M | — |
hisa zilizosalia | 12.00M | — |
Uwiano wa bei na thamani | -49.58 | — |
Faida inayotokana na mali | -11.81% | — |
Faida inayotokana mtaji | -17.26% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -10.69M | -187.82% |
Pesa kutokana na shughuli | -3.81M | -210.31% |
Pesa kutokana na uwekezaji | elfu -322.50 | -100.69% |
Pesa kutokana na ufadhili | -20.11M | -4.52% |
Mabadiliko halisi ya pesa taslimu | -24.31M | -178.80% |
Mtiririko huru wa pesa | -4.62M | -154.24% |
Kuhusu
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
Okt 2000
Tovuti
Wafanyakazi
147
